Authors: Breast Cancer Expert Committee of the National Quality Control Center for Cancer, Expert Committee on Cancer Prevention and Treatment of the Health China Research Center, Society of Clinical Research on Oncology Medications of the China Anti‐Cancer Association, Society of Onco‐Pathology of the China Anti‐Cancer Association.
DOI: 10.1002/cai2.70008
Abstract Summary
Chinese experts updated their 2022 consensus on PI3K/AKT/mTOR inhibitors for advanced breast cancer treatment. The 2025 edition includes newly approved drugs, latest clinical trial data, expanded therapeutic uses, and enhanced genetic testing recommendations. Significantly improved guidance on managing adverse events aims to boost precision medicine and patient survival outcomes.
Why Brain? 🧠
New consensus updates guidance on PI3K/AKT/mTOR inhibitors for breast cancer, adding newly approved drugs, expanded adverse event management, and genetic testing recommendations to improve patient outcomes.
License: cc by.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
